195 related articles for article (PubMed ID: 36701935)
21. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.
Miles J; Treitler P; Hermida R; Nyaku AN; Simon K; Gupta S; Crystal S; Samples H
Drug Alcohol Depend; 2023 Nov; 252():110963. PubMed ID: 37748421
[TBL] [Abstract][Full Text] [Related]
22. A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
Sujan A; Cleary E; Douglas E; Aujla R; Boyars L; Smith C; Guille C
Fam Pract; 2022 Mar; 39(2):311-315. PubMed ID: 34537839
[TBL] [Abstract][Full Text] [Related]
23. The cascade of care for opioid use disorder among youth in British Columbia, 2018.
Krebs E; Min JE; Zhou H; Davison C; McGowan G; Nosyk B
J Subst Abuse Treat; 2021 Nov; 130():108404. PubMed ID: 34118696
[TBL] [Abstract][Full Text] [Related]
24. Dental care utilization in Massachusetts before and after initiation of medication for opioid use disorder: A cross-sectional study of a state all-payer claims database.
Simon L; Choudhary A; Ticku S; Barrow J; Tobey M
J Public Health Dent; 2022 Sep; 82(4):461-467. PubMed ID: 34816438
[TBL] [Abstract][Full Text] [Related]
25. Provider-directed marketing may increase prescribing of medications for opioid use disorder.
Nguyen T; Andraka-Christou B; Simon K; Bradford WD
J Subst Abuse Treat; 2019 Sep; 104():104-115. PubMed ID: 31370974
[TBL] [Abstract][Full Text] [Related]
26. Changes In County-Level Access To Medications For Opioid Use Disorder After Medicare Coverage Of Methadone Treatment Began.
Harris SJ; Yarbrough CR; Abraham AJ
Health Aff (Millwood); 2023 Jul; 42(7):991-996. PubMed ID: 37406230
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder.
Dowd WN; Barch DH; Seibert JH; Mark TL
J Subst Abuse Treat; 2022 Sep; 140():108824. PubMed ID: 35780730
[TBL] [Abstract][Full Text] [Related]
28. Gender disparities in opioid treatment progress in methadone versus counseling.
Guerrero E; Amaro H; Kong Y; Khachikian T; Marsh JC
Subst Abuse Treat Prev Policy; 2021 Jun; 16(1):52. PubMed ID: 34162420
[TBL] [Abstract][Full Text] [Related]
29. Outcomes Associated with Treatment with and Without Medications for Opioid Use Disorder.
Mutter R; Spencer D; McPheeters J
J Behav Health Serv Res; 2023 Oct; 50(4):524-539. PubMed ID: 37311970
[TBL] [Abstract][Full Text] [Related]
30. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
[TBL] [Abstract][Full Text] [Related]
31. Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults.
Welsh JW; Dennis ML; Funk R; Mataczynski MJ; Godley MD
J Subst Abuse Treat; 2022 Jan; 132():108584. PubMed ID: 34391589
[TBL] [Abstract][Full Text] [Related]
32. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
[TBL] [Abstract][Full Text] [Related]
33. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
Mauro PM; Gutkind S; Annunziato EM; Samples H
JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
[TBL] [Abstract][Full Text] [Related]
34. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
35. Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.
Andraka-Christou B; Saloner B; Gordon AJ; Totaram R; Randall-Kosich O; Golan M; Stein BD
Am J Drug Alcohol Abuse; 2022 Jul; 48(4):492-503. PubMed ID: 35772010
[No Abstract] [Full Text] [Related]
36. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis.
Savinkina A; Madushani RWMA; Eftekhari Yazdi G; Wang J; Barocas JA; Morgan JR; Assoumou SA; Walley AY; Linas BP; Murphy SM
Addiction; 2022 Sep; 117(9):2450-2461. PubMed ID: 35315162
[TBL] [Abstract][Full Text] [Related]
37. Maternal opioid use disorder and infant mortality in Wisconsin, United States, 2010-2018.
Mallinson DC; Kuo HD; Kirby RS; Wang Y; Berger LM; Ehrenthal DB
Prev Med; 2024 Apr; 181():107914. PubMed ID: 38408650
[TBL] [Abstract][Full Text] [Related]
38. Factors associated with receipt of medication for opioid use disorder among pregnant individuals entering treatment programs in the U.S.
Curran L; Manuel J
Int J Drug Policy; 2024 Apr; 126():104342. PubMed ID: 38479161
[TBL] [Abstract][Full Text] [Related]
39. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
Treitler PC; Enich M; Reeves D; Crystal S
Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
[No Abstract] [Full Text] [Related]
40. A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.
Presnall NJ; Wolf DAPS; Brown DS; Beeler-Stinn S; Grucza RA
J Subst Abuse Treat; 2019 Sep; 104():135-143. PubMed ID: 31370977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
